公开(公告)号：US20210024650A1

公开(公告)日：2021-01-28

申请号：US16939536

申请日：2020-07-27

Applicant: ABL Bio Inc. ,  YUHAN CORPORATION

Inventor： Hyejin CHUNG ,  Yeryoung Yong ,  Kyeongsu Park ,  Eunyoung Park ,  Ui-Jung Jung ,  Yangsoon Lee ,  Eunjung Kim ,  Yong-Gyu Son ,  Wonjun Son ,  Seawon Ahn ,  Donghoon Yeom ,  Chanmoo Lee ,  Junghyeon Hong ,  Moo Young Song ,  Eun-Jung Lee ,  Na Rae Lee ,  Young Bong Park ,  Eun-Jung Lee ,  Taewang Kim

IPC: C07K16/32 ,  C07K16/28 ,  A61P35/00

Abstract: Provided are an anti-4-1BB/anti-HER2 bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

公开(公告)号：US11891445B1

公开(公告)日：2024-02-06

申请号：US17057643

申请日：2019-05-24

Applicant: ABL Bio Inc.

Inventor： Kyeongsu Park ,  Yangsoon Lee ,  Hyejin Chung ,  Uijung Jung ,  Yong-Gyu Son ,  Sang-Jun Ha ,  Myeong Joon Kim ,  Eunyoung Park ,  Kyungjin Park ,  Eunsil Sung ,  Yeunju Kim ,  Jinhyung Ahn ,  Byungje Sung ,  Daehae Song ,  Youngdon Pak

IPC: C07K16/28 ,  G01N33/574 ,  A61P35/00 ,  A61K39/00

CPC classification number: C07K16/2827 ,  A61P35/00 ,  G01N33/57492 ,  A61K2039/505 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  G01N2333/70532

Abstract: Provided is an anti-B7-H3 antibody specifically recognizing a B7-H3, which can be usefully as a cancer therapeutic agent, as having an inhibitory activity of an immune checkpoint which induces antibody-dependent cell-mediated cytotoxicity and T cell activation inhibited by B7-H3. In particular, the antibody having the inhibitory activity of an immune checkpoint can be used in combination with other immunoantibody therapeutic agents. In addition, it can be usefully used for cancer targeting treatment including detection of various cancers expressing B7-H3 through specific binding to B7-H3, and drug delivery to specific cancer, etc.

公开(公告)号：US12195538B2

公开(公告)日：2025-01-14

申请号：US17298741

申请日：2019-02-15

Applicant: ABL BIO INC. ,  I-MAB BIOPHARMA US LIMITED

Inventor： Eunyoung Park ,  Yangsoon Lee ,  Hyejin Chung ,  Eunsil Sung ,  Jiseon Yoo ,  Minji Park ,  Yong-Gyu Son ,  Hyoju Choi ,  Eunjung Kim ,  Jaeho Jung ,  Weon-Kyoo You ,  Sang Hoon Lee ,  Lei Fang ,  Wenqing Jiang

IPC: C07K16/28 ,  A61P35/00 ,  C07K16/46

Abstract: The present disclosure provides an anti-PD-L1/anti-4-1BB bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between 4-1BB and its ligand. The bispecific antibody may have high binding affinity to both of a PD-L1 protein and a 4-1BB protein.

公开(公告)号：US12071483B1

公开(公告)日：2024-08-27

申请号：US16770728

申请日：2018-12-14

Applicant: ABL Bio Inc.

Inventor： Jinhyung Ahn ,  Sungwon An ,  Dongin Kim ,  Eunsil Sung ,  Jaehyun Eom ,  Sang Hoon Lee ,  Weonkyoo You ,  Juhee Kim ,  Kyungjin Park ,  Hyejin Chung ,  Jinwon Jung ,  Bora Lee ,  Byungje Sung ,  Yeunju Kim ,  Yong-Gyu Son ,  Seawon Ahn ,  Daehae Song ,  Jiseon Yoo ,  Youngdon Pak ,  Donghoon Yeom ,  Yoseob Lee ,  Jaeho Jung

IPC: A61K39/395 ,  A61K47/68 ,  C07K16/18 ,  C07K16/28

CPC classification number: C07K16/2863 ,  A61K47/6845 ,  C07K16/18 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/567

Abstract: The present invention relates to a bi-specific antibody that specifically binds to alpha-synuclein and IGF1R, and use of the bi-specific antibody for treating or diagnosing synucleinopathies associated with alpha-synuclein or alpha-synuclein aggregates. The IGF1R portion of the bi-specific antibody acts as a shuttle to penetrate the blood brain barrier, allowing the alpha-synuclein portion to exert its action in the brain. Further, the half-life of the bi-specific antibody may be extended to maintain efficacy over time.